
AI Digest · Eli Lilly's retatrutide approval before 2028 gains ground as FDA tightens GLP-1 eye warnings
Kalshi traders favor the FDA approving drugmaker Eli Lilly's retatrutide before Jan 1, 2028, and that view gained ground this week. The FDA is making makers of GLP-1 drugs like Ozempic and Zepbound add warnings about a rare blinding eye condition, The Hill reports. The warning covers drugs already on the market, and the notice does not name retatrutide. Retatrutide is Lilly's experimental weight-loss drug, and the FDA has not yet approved it.